Novo Nordisk shares drop

Novo’s New Obesity Drug Disappoints Again, This Time in Diabetes
Novo Nordisk A/S shares fell the most since December after the drugmaker’s next-generation shot CagriSema showed 15.7% weight loss in a clinical trial of people with diabetes.
Novo Nordisk trial with next-gen diabetes drug shows 15.7% weight loss but shares fall
Novo Nordisk said on Monday its experimental next-generation drug CagriSema helped overweight or obese patients with type 2 diabetes cut their weight by 15.7% after 68 weeks, but shares fell, likely on the lower-than-expected weight loss.
Novo Nordisk shares drop after next-gen obesity drug disappoints in diabetes trial
Novo Nordisk reported results on its next-generation obesity drug in diabetes patients, including data on weight loss that fell short of investors’ expectations.
Novo Nordisk under pressure as obesity drug disappoints in diabetes trial
Shares of Novo Nordisk (NVO) are sliding in Monday trading after the company announces results for its trial of weight-loss drug CagriSema.
Data on new Novo Nordisk obesity drug disappoints in trial, shares drop
Novo Nordisk on Monday revealed weaker-than-expected data from a second late-stage trial of its obesity drug candidate CagriSema, knocking shares and stoking worries that rival Eli Lilly may be gaining an edge over the company in the weight-loss drugs market.
Why Novo Nordisk Stock Is Falling Today
The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss treatment. The current generation, made up of blockbuster drugs like Wegovy and Ozempic, have been cash cows for Novo.
Fierce Pharma4d
Novo Nordisk invites people with Type 2 diabetes into their ‘Ozempic Eras’ in star-studded campaign
In a statement, Trotter described his experience as a child with older relatives who struggled with Type 2 diabetes. Trotter ...
Biznews9d
🔒 Novo’s insulin pen phase-out sparks CompCom probe as diabetes remains a silent killer among SA women
South Africa's Competition Commission investigates Novo Nordisk and Sanofi for potential anti-competitive practices in the insulin pen market.
Novo Nordisk's Ozempic successor disappointed Wall Street again
Novo Nordisk (NVO) released clinical trial results for its potential Ozempic successor on Monday, disappointing Wall Street ...
BioPharma Dive3d
Novo’s Wegovy successor disappoints in second large trial
A study in people with obesity and diabetes again found CagriSema helps people lose weight, but not by enough to clearly ...
BioSpace9d
Novo, Sanofi Hit With Anti-Competitive Probe in South Africa: Bloomberg
The last few years have been tough for the insulin market, with recent policies and high-level pressure forcing companies to ...